GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3387)

  • GC70753 structure
    GC70753PDK4-IN-1
    CAS: 2310262-10-1
    Purity: >98.00%

    PDK4-IN-1はアントラキノン誘導体と強力な経口活性ピルビン酸デヒドロゲナーゼキナーゼ4(PDK 4)阻害剤であり、IC 50値は84 nMである。

  • GC70756 structure
    GC70756Cytarabine-d2
    CAS: 40632-26-6
    Purity: >98.00%

    Cytarabine-d2は重水素標識されたアスコシドである。

  • GC70759 structure
    GC70759AQX-435
    CAS: 1619983-52-6
    Purity: >99.00%

    AQX-435は強力なSHIP 1ホスファターゼ活性剤である。

  • GC70853 structure
    GC70853Broussochalcone A
    CAS: 99217-68-2
    Purity: >97.00%

    Broussochalcone Aは抗酸化物質として作用し、とXanthineオキシダーゼの阻害物質(IC50 =μ2.21 M)フリーラジカルを活動。

  • GC70868 structure
    GC70868Nrf2 activator-3
    CAS: 2766570-23-2
    Purity: >98.00%

    Nrf2 activator-3は要りNrf2押してください

  • GC70875 structure
    GC70875RIPK1-IN-9
    CAS: 2682889-57-0

    RIPK1-IN-9(実施例45)は、強力で選択的なRIPK 1阻害剤であるジヒドロナフタジノン化合物である。

  • GC70941 structure
    GC70941ISIS 104838 sodium
    Purity: >93.00%

    ISIS 104838 sodium is an antisense oligonucleotide agent that reduces the production of tumor necrosis factor (TNF-alpha), a substance that contributes to joint pain and swelling in rheumatoid arthritis.

  • GC71008 structure
    GC71008BBR-BODIPY
    CAS: 2456476-47-2
    Purity: >98.00%

    BBR-BODIPYは、標的細胞との相互作用をスクリーニングする蛍光プローブです。

  • GC71031 structure
    GC71031Nrf2 activator-6
    CAS: 2728780-74-1

    Nrf2 activator-6 テトラヒドロイソキノリン化合物はNrf 2活性化剤である。

  • GC71050 structure
    GC71050Oditrasertib
    CAS: 2252271-93-3
    Purity: >98.00%

    Oditrasertib は100 nM未満のIC 50値を有する受容体相互作用蛋白質キナーゼ1(RIPK 1)阻害剤である。

  • GC71072 structure
    GC71072NXPZ-2
    CAS: 2254492-08-3
    Purity: >98.00%

    NXPZ-2 は経口活性Keap 1-Nrf 2タンパク質-タンパク質相互作用(PPI)阻害剤であり、Ki値は95 nM、EC 50値は120と170 nMである。

  • GC71119 structure
    GC71119UBX1325
    CAS: 2271269-01-1
    Purity: >98.00%

    UBX1325 は老化細胞のアポトーシスを促進するBcl−xL阻害剤である。

  • GC71128 structure
    GC71128Diclofenac-d4 sodium
    CAS: 154523-54-3
    Purity: >99.00%

    Diclofenac-d4 sodium は重水素標識ジクロルファン酸ナトリウムである。

  • GC71180 structure
    GC71180SZM679
    CAS: 3027645-52-6
    Purity: >99.00%

    SZM679 は強力で経口活性と選択的なRIPK 1阻害剤であり、RIPK 1とRIPK 3のKd値はそれぞれ8.6 nMと>5000 nMである。

  • GC71214 structure
    GC71214CZL55
    CAS: 667408-87-9
    Purity: >98.00%

    CZL55はシステアスパラギン-1阻害剤であり、IC 50値は24 nMである。

  • GC71232 structure
    GC71232I-152
    CAS: 311343-11-0
    Purity: >98.00%

    I-152はn-アセチルシステイン(nac)とシステアミン(mea)を含む共役体である。

  • GC71258 structure
    GC71258ASK1-IN-4
    CAS: 1427538-26-8

    ASK1-IN-4(化合物17)はASK 1阻害剤(IC 50=0.2μM)である。

  • GC71298 structure
    GC71298DRI-C21041 (DIEA)

    DRI-C21041 (DIEA)は、CD40 /剤の対話をCD40L、のIC50 0.31μM。

  • GC71355 structure
    GC71355Zharp2-1
    CAS: 2772600-18-5
    Purity: >99.00%

    Zharp2-1 は、炎症性腸疾患(ibd)に強く関連する経口有効なripk2阻害剤です。

  • GC71380 structure
    GC71380UCB-6876
    CAS: 637324-45-9
    Purity: >99.00%

    UCB-6876 はバトン渡しTNFα剤の結合非対称水晶形状をTNF trimer (KD = 22μM)。

  • GC71507 structure
    GC715075'-Methylthioadenosine-13C6
    CAS: 2421187-73-5

    5'-Methylthioadenosine-13C6は13 C標識の5'-メチオニジンである。

  • GC71541 structure
    GC71541BMS-561392 formate
    CAS: 2922280-85-9

    BMS-561392 formateはBMS-561392のギ酸塩形態である。

  • GC71544 structure
    GC71544Antroquinonol
    CAS: 1010081-09-0
    Purity: >98.00%

    Antroquinonol((+)-Antroquinonol)、キノコAntrodia camphorataから抽出されたパントキノン誘導体であり、肝臓保護、抗炎症、抗癌作用を有する。

  • GC71607 structure
    GC71607Melatonin-d7
    CAS: 615251-68-8
    Purity: >98.00%

    Melatonin-d7は重水素標識メラトニンである。